SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Par Pharmaceutical Companies Inc. In Connection With The Sale Of The Company To TPG
Levi & Korsinsky is investigating the Board of Directors of Par Pharmaceutical Companies Inc. (“Par” or the “Company”) (NYSE: PRX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to the private equity firm TPG. Click here to learn how to join the action: http://zlk.9nl.com/par-pharmaceutical-companies-prx, or call: 877-363-5972. There is no cost or obligation to you. Under the terms of the transaction, Par shareholders will receive $50 per share of Par stock they own. The transaction has an approximate total value of $1.9 billion. The investigation concerns whether the Par Board of Directors breached their fiduciary duties to Par stockholders by failing to adequately shop the Company before entering into this transaction and whether TPG is underpaying for Par shares, thus unlawfully harming Par stockholders. If you own common stock in Par and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or http://zlk.9nl.com/par-pharmaceutical-companies-prx. Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.